ProCE Banner Series

Mastering Asparaginase Regimens in the Care of Pediatric and AYA Patients with Acute Lymphoblastic Leukemia

This satellite symposium will provide expert perspectives on how to optimize clinical outcomes with the use of asparaginase-based therapy for pediatric and adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL), including information on evidence-based strategies to effectively prevent, mitigate, and manage the associated adverse events in the personalization of patient care.

Who Should Attend

This program is intended for pediatric oncologists and other healthcare professionals caring for children, adolescents, and young adults with ALL.

All Events

Mastering Asparaginase Regimens in the Care of Pediatric and AYA Patients With Acute Lymphoblastic Leukemia

Past Events




11:15 AM - 12:30 PM Pacific Time (PT)


Seattle Convention Center, 705 Pike Street, Seattle, Washington 98101-2310

11:30 AM - 12:30 PM Pacific Time (PT)



ProCE Banner Faculty
Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

ProCE Banner Faculty
Stephen P. Hunger, MD

Jeffrey E. Perelman Distinguished Chair in Pediatrics
Chief, Division of Pediatric Oncology
Director, Center for Childhood Cancer Research
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania


Asparaginase-Based Regimens for Pediatric and AYA Patients With ALL

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.


Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Acute Lymphoblastic Leukemia (ALL).

Target Audience
This program is intended for pediatric oncologists and other healthcare professionals caring for children, adolescents, and young adults with ALL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Delineate optimal methods of identifying, measuring, and monitoring AEs associated with asparaginase therapies, including subclinical hypersensitivity and silent inactivation, in the pediatric and AYA population undergoing treatment for ALL
  • Determine instances when introducing alternative formulations of asparaginase is appropriate, in alignment with established best practices for both re-exposure to asparaginase preparations and use of recombinant asparaginase
  • Modify asparaginase-based treatment regimens, using evidence-based agents and approaches, to address hypersensitivity reactions and increase completion rates of asparaginase treatment in patients with ALL
  • Evaluate current clinical evidence and expert recommendations for implementing pediatric-inspired therapeutic regimens for ALL into treatment plans for adolescents and young adults


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.  


Provided by Clinical Care Options, LLC

Supported by an educational grant from Jazz Pharmaceuticals, Inc.